Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026 Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading global pharmaceutical company, has achieved a significant milestone by receiving Good Manufacturing Practices (GMP) certification from
Oncology drugs constitute the largest proportion of the Serbian pharmaceutical market, where Venus Remedies has so far secured five marketing approvals, all in the oncology space The company is banking on the product registration from Serbia to pave the way for faster approvals for
Join 2M+ industry professionals with MedgateToday - curated insights, delivered daily.
